|Lymphovascular invasion in rectal cancer following neoadjuvant radiotherapy: A retrospective cohort study|
|Du, Chang-Zheng1; Xue, Wei-Cheng2; Cai, Yong3; Li, Ming1; Gu, Jin1|
|关键词||Lymphovascular Invasion Rectal Cancer Neoadjuvant Radiotherapy Total Mesorectal Excision Pathology Prognosis|
|刊名||WORLD JOURNAL OF GASTROENTEROLOGY|
|WOS标题词||Science & Technology|
|类目[WOS]||Gastroenterology & Hepatology|
|研究领域[WOS]||Gastroenterology & Hepatology|
|关键词[WOS]||DISEASE-FREE SURVIVAL ; PREOPERATIVE RADIOTHERAPY ; COLORECTAL-CANCER ; RADIATION ; CHEMORADIATION ; RECURRENCE ; MECHANISM ; CARCINOMA ; THERAPY ; DAMAGE|
AIM: To investigate the meaning of lymphovascular invasion (LVI) in rectal cancer after neoadjuvant radiotherapy.
METHODS: A total of 325 patients who underwent radical resection using total mesorectal excision (TME) from January 2000 to January 2005 in Beijing cancer hospital were included retrospectively, divided into a preoperative radiotherapy (PRT) group and a control group, according to whether or not they underwent preoperative radiation. Histological assessments of tumor specimens were made and the correlation of LVI and prognosis were evaluated by univariate and multivariate analysis.
RESULTS: The occurrence of LVI in the PRT and control groups was 21.4% and 26.1% respectively. In the control group, LVI was significantly associated with histological differentiation and pathologic TNM stage, whereas these associations were not observed in the PRT group. LVI was closely correlated to disease progression and 5-year overall survival (OS) in both groups. Among the patients with disease progression, LVI positive patients in the PRT group had a significantly longer median disease-free period (22.5 mo vs 11.5 mo, P = 0.023) and overall survival time (42.5 mo vs 26.5 mo, P = 0.035) compared to those in the control group, despite the fact that no significant difference in 5-year OS rate was observed (54.4% vs 48.3%, P = 0.137). Multivariate analysis showed the distance of tumor from the anal verge, pretreatment serum carcinoembryonic antigen level, pathologic TNM stage and LVI were the major factors affecting OS.
CONCLUSION: Neoadjuvant radiotherapy does not reduce LVI significantly; however, the prognostic meaning of LVI has changed. Patients with LVI may benefit from neoadjuvant radiotherapy. (C) 2009 The WJG Press and Baishideng. All rights reserved.
|资助机构||Peking University School of Oncology|
|作者单位||1.Peking Univ, Sch Oncol, Dept Colorectal Surg, Beijing 100142, Peoples R China|
2.Peking Univ, Sch Oncol, Dept Pathol, Beijing 100142, Peoples R China
3.Peking Univ, Sch Oncol, Dept Radiotherapy, Beijing 100142, Peoples R China
|Du, Chang-Zheng,Xue, Wei-Cheng,Cai, Yong,et al. Lymphovascular invasion in rectal cancer following neoadjuvant radiotherapy: A retrospective cohort study[J]. WORLD JOURNAL OF GASTROENTEROLOGY,2009,15(30):3793-3798.|
|APA||Du, Chang-Zheng,Xue, Wei-Cheng,Cai, Yong,Li, Ming,&Gu, Jin.(2009).Lymphovascular invasion in rectal cancer following neoadjuvant radiotherapy: A retrospective cohort study.WORLD JOURNAL OF GASTROENTEROLOGY,15(30),3793-3798.|
|MLA||Du, Chang-Zheng,et al."Lymphovascular invasion in rectal cancer following neoadjuvant radiotherapy: A retrospective cohort study".WORLD JOURNAL OF GASTROENTEROLOGY 15.30(2009):3793-3798.|